PMID- 9987206
OWN - NLM
STAT- MEDLINE
DCOM- 19990316
LR  - 20181201
IS  - 1180-4882 (Print)
IS  - 1488-2434 (Electronic)
IS  - 1180-4882 (Linking)
VI  - 24
IP  - 1
DP  - 1999 Jan
TI  - Treatment of bipolar mixed state with olanzapine.
PG  - 40-4
AB  - OBJECTIVE: An open trial was conducted to determine the efficacy of olanzapine in 
      the treatment of bipolar mixed state. PARTICIPANTS: Nine inpatients at a 
      provincial psychiatric hospital who met the DSM-IV criteria for bipolar I 
      disorder, most recent episode mixed. INTERVENTION: Olanzapine was added to the 
      existing drug regime in patients who had failed to respond to adequate trials of 
      mood stabilizers used alone or in combination with neuroleptics. OUTCOME 
      MEASURES: Patients were administered the Clinical Global Impression (CGI) Scale, 
      the Brief Psychiatric Rating Scale (BPRS) and the Global Assessment of 
      Functioning (GAF) Scale before the initiation of olanzapine. These scales were 
      repeated and patients were rated on the improvement subscale of the CGI at the 
      time of discharge. RESULTS: Pretreatment means (and standard deviations [SD]) for 
      the CGI scale, BPRS and GAF were 5.7 (1.1), 60.7 (13.7) and 17.8 (7.5), 
      respectively. Post-treatment means and SD for the scales were 1.9 (0.6), 6.3 
      (3.3) and 71.7 (5.6), respectively. Paired t-tests on all measures indicated 
      significant improvement in symptoms with t = 9.43, p < 0.001 for CGI; t = -13.28, 
      p < 0.001 for BPRS; t = -21.83, p < 0.001 for GAF. The mean improvement subscale 
      score of the CGI was 1.3 (SD 0.5) at discharge. CONCLUSIONS: Olanzapine was 
      well-tolerated and was effective in the acute treatment of bipolar mixed state.
FAU - Sharma, V
AU  - Sharma V
AD  - Mood Disorders Unit, London Psychiatric Hospital, ON. vsharma@julian.uwo.ca
FAU - Pistor, L
AU  - Pistor L
LA  - eng
PT  - Journal Article
PL  - Canada
TA  - J Psychiatry Neurosci
JT  - Journal of psychiatry & neuroscience : JPN
JID - 9107859
RN  - 0 (Antipsychotic Agents)
RN  - 12794-10-4 (Benzodiazepines)
RN  - 3G0285N20N (Pirenzepine)
RN  - N7U69T4SZR (Olanzapine)
SB  - IM
MH  - Adult
MH  - Antipsychotic Agents/adverse effects/*therapeutic use
MH  - Benzodiazepines
MH  - Bipolar Disorder/diagnosis/*drug therapy
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Olanzapine
MH  - Pirenzepine/adverse effects/*analogs & derivatives/therapeutic use
MH  - Psychiatric Status Rating Scales
MH  - Treatment Outcome
PMC - PMC1188975
EDAT- 1999/02/13 00:00
MHDA- 1999/02/13 00:01
PMCR- 1999/01/01
CRDT- 1999/02/13 00:00
PHST- 1999/02/13 00:00 [pubmed]
PHST- 1999/02/13 00:01 [medline]
PHST- 1999/02/13 00:00 [entrez]
PHST- 1999/01/01 00:00 [pmc-release]
PST - ppublish
SO  - J Psychiatry Neurosci. 1999 Jan;24(1):40-4.